Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Condition: Pharmacokinetics, Pharmacodynamics, Insulin Aspart Interventions: Drug: I004; Drug: NovoLog Sponsor: Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Conditions: Pharmacokinetics; Pharmacodynamics Interventions: Drug: I004; Drug: NovoLog Sponsor: Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Condition: Pharmacokinetics, Pharmacodynamics, Insulin Aspart Interventions: Drug: I004; Drug: NovoLog Sponsor: Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Conditions: Pharmacokinetics; Pharmacodynamics Interventions: Drug: I004; Drug: NovoLog Sponsor: Amphastar Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2022 Category: Research Source Type: clinical trials
AT247, NovoLog ® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Condition: Diabetes Mellitus, Type 1 Interventions: Drug: AT247; Drug: NovoLog; Drug: Fiasp Sponsor: Arecor Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2022 Category: Research Source Type: clinical trials